Who can use Cablivi(Caplacizumab)?

CABLIVI is indicated for use in adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) as part of a combination treatment regimen.

Approved Indication and Patient Population

CABLIVI (caplacizumab-yhdp) is approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP). It must be used concomitantly with plasma exchange and immunosuppressive therapy, forming a critical component of the combined therapeutic approach for this thrombotic microangiopathy.